APL invests 40 Million SEK in Umeå
APL (Apotek Production & Laboratorier AB) is committing 40 million SEK to establish a new sterile pharmaceutical production line at its Umeå site. This strategic move is both a response to new manufacturing regulations and an enhancement of the plant’s output capabilities, including acquiring new machinery and constructing additional facilities.
“The dynamic environment in Umeå is perfectly suited for our growth,” says Erik Haeffler, CEO of APL, to UBI.